NEW YORK – Having closed an $11 million funding round, Singapore-based immune profiling firm ImmunoScape is now looking to launch operations in the US.
The A*STAR of Singapore spin-out aims to open a US facility by the end of the year and begin running collaborations out of that location in the first quarter of 2021, said Choon-Peng Ng, the company's co-founder and CEO.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
